Cargando…

CDK4/6 inhibition alone and in combination for non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	Pacheco, Jose, Schenk, Erin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	News
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363011/ https://www.ncbi.nlm.nih.gov/pubmed/30774754 http://dx.doi.org/10.18632/oncotarget.26545

Ejemplares similares

SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
por: Xue, Yibo, et al.
Publicado: (2019)

Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations
por: Pacheco, Jose, et al.
Publicado: (2021)

CDK8: a new breast cancer target
por: Crown, John
Publicado: (2017)

Cdk5 protects huntingtin
por: LeBrasseur, Nicole
Publicado: (2005)

CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
por: Rampioni Vinciguerra, Gian Luca, et al.
Publicado: (2022)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
por: Gopalan, Priya K., et al.
Publicado: (2018)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

CDK1 makes the meiotic spindle wait
por: Short, Ben
Publicado: (2013)

CDK5 opens the way for DLC1
por: Short, Ben
Publicado: (2014)

Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer
por: Wang, Yuxiang, et al.
Publicado: (2019)

Keeping CDK18 in balance to prevent DNA replication stress in breast cancer
por: Braams, Esmée, et al.
Publicado: (2018)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion
por: Velez, Brian Christopher, et al.
Publicado: (2022)

Erratum to Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer
por: Wang, Yuxiang, et al.
Publicado: (2019)

Clathrin starts off alone
por: Wells, William A.
Publicado: (2004)

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas
por: Pita, Jaime M., et al.
Publicado: (2023)

CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer
por: Iyengar, Mangala, et al.
Publicado: (2018)

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
por: Ge, Jennifer Y., et al.
Publicado: (2020)

Unexpected Outcomes of CDK4/6 Inhibition
por: Choi, Yoon Jong, et al.
Publicado: (2013)

Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma
por: Ke, Yuan, et al.
Publicado: (2022)

Small cell lung cancers made from scratch
por: Gazdar, Adi F., et al.
Publicado: (2019)

The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer
por: Zhou, Wei, et al.
Publicado: (2023)

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
por: Pacheco, Jose M., et al.
Publicado: (2019)

Anticancer Effects of Amlodipine Alone or in Combination With Gefitinib in Non-Small Cell Lung Cancer
por: Fu, Bingjie, et al.
Publicado: (2022)

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer
por: Plangger, Adelina, et al.
Publicado: (2021)

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2019)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
por: Portman, Neil, et al.
Publicado: (2020)

CDK4/6 inhibition in cancer: the cell cycle splicing connection
por: Sheppard, Karen E., et al.
Publicado: (2019)

CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines
por: Wright, Gabriela M., et al.
Publicado: (2021)

Cyclin-dependent kinase 6 (CDK6) is a candidate diagnostic biomarker for early non-small cell lung cancer
por: Gong, Wangang, et al.
Publicado: (2020)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
por: Gelbert, Lawrence M., et al.
Publicado: (2014)

CDK7 is a prognostic biomarker for non-small cell lung cancer
por: Kuempers, Christiane, et al.
Publicado: (2022)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis
por: Birnhuber, Anna, et al.
Publicado: (2020)

EphA2 cleavage helps tumor cells go it alone
por: Short, Ben
Publicado: (2013)

CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
por: Nardone, Valerio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g0rqadfcg726v8lvbem2qnkggo